Moreover, diverse experimentation demonstrated that myeloma cell proliferation was linked with modifications of activity and phenotypic changes in bone marrow ILC2s, with an augmented presence of maturation markers and decreased cytokine response to IL-2/IL-33 [153]. This evidence concerns the gene IL33 and plasma cell myeloma.